Neutralizing antibodies in patients with chronic hepatitis C infection treated with (Peg)-interferon/ribavirin

Boo, Irene; Fischer, Alexandra E.; Johnson, Doug; Chin, Rey; Giourouki, Maxine; Bharadwaj, Mandvi; Bowden, Scott; Torresi, Joseph; Drummer, Heidi E.

doi:10.1016/j.jcv.2007.04.019

Cited by 12 publications

(11 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These numbers are small, but differ from the results of Boo et al 24 who showed that in a collective of 17 patients neutralizing anti-HCVpp antibody is not correlated with response to antiviral therapy. The VSVpp control experiment showed positive reactions in some patient samples (Table 2), this was the case when HCV negative patients were analyzed, too (Table 3).…”

Section: Discussioncontrasting

confidence: 99%

Measurements of HCV neutralizing antibodies and of HCV-specific CD4+ and CD8+ cells using hepatitis C virus pseudo-particles (HCVpp)

Berger

Giroglou

Leutz

et al. 2009

Journal of Clinical Virology

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 99%

Measurements of HCV neutralizing antibodies and of HCV-specific CD4+ and CD8+ cells using hepatitis C virus pseudo-particles (HCVpp)

Berger

Giroglou

Leutz

et al. 2009

Journal of Clinical Virology

View full text Add to dashboard Cite

“…Only two studies have looked at the predictive value of NAb on treatment effect but with contradictive results [31], [32]. Thus, there is a need for further investigation in this research area.…”

Section: Introductionmentioning

confidence: 99%

Neutralizing Antibodies in Patients with Chronic Hepatitis C, Genotype 1, against a Panel of Genotype 1 Culture Viruses: Lack of Correlation to Treatment Outcome

et al. 2013

View full text Add to dashboard Cite

The correlation of neutralizing antibodies to treatment outcome in patients with chronic hepatitis C virus (HCV) infection has not been established. The aim of this study was to determine whether neutralizing antibodies could be used as an outcome predictor in patients with chronic HCV, genotype 1, infection treated with pegylated interferon-α and ribavirin. Thirty-nine patients with chronic hepatitis C, genotype 1a or 1b, with either sustained virologic response (n = 23) or non-sustained virologic response (n = 16) were enrolled. Samples taken prior to treatment were tested for their ability to neutralize 6 different HCV genotype 1 cell culture recombinants (1a: H77/JFH1, TN/JFH1, DH6/JFH1; 1b: J4/JFH1, DH1/JFH1, DH5/JFH1). The results were expressed as the highest dilution yielding 50% neutralization (NAb50-titer). We observed no genotype or subtype specific differences in NAb50-titers between patients with chronic HCV infection with and without sustained virologic response when tested against any of the included culture viruses. However, NAb50-titers varied significantly with a mean reciprocal NAb50-titer of 800 (range: 100–6400) against DH6/JFH1 compared to a mean NAb50-titer of 50 (range: <50–400) against all other included isolates. Subsequent studies demonstrated that the efficient neutralization of DH6/JFH1 could be linked to engineered adaptive mutations in the envelope-2 protein. In analysis of envelope 1 and 2 sequences of HCV, recovered from a subset of patients, we observed no apparent link between relatedness of patient sequences with culture viruses used and the corresponding neutralization results. In conclusion, pre-treatment levels of neutralizing antibodies against HCV genotype 1 isolates could not predict treatment outcome in patients with chronic HCV infection. High neutralization susceptibility of DH6/JFH1 could be correlated with adaptive envelope mutations previously highlighted as important for neutralization. Our study emphasizes the importance of using multiple culture viruses for neutralization studies and contributes to the current knowledge about neutralizing epitopes, important for future therapeutic- and vaccine-studies.

show abstract

“…Vallbracht et al [27] first reported the development of neutralizing immunoglobulin-G antibodies against natural human fibroblast IFN in a patient treated with the said IFN in 1981. Furthermore, several studies have reported neutralizing anti-IFN antibodies due to administration of IFN [28][29][30][31][32][33][34][35] . Achievement of a complete SVR in patients with HCV infection by switching the previously administered IFN with another has been reported in several studies [2,5,36] .…”

Section: Discussionmentioning

confidence: 99%

Achievement of Sustained Viral Response after Switching Treatment from Pegylated Interferon a-2b to a-2a and Ribavirin in Patients with Recurrence of Hepatitis C Virus Genotype 1 Infection after Liver Transplantation: A Case Report

Kawaoka¹,

Hiraga²,

Takahashi³

et al. 2012

Intervirology

View full text Add to dashboard Cite

We report a case in which sustained viral response was achieved after switching treatment from pegylated interferon (PEG-IFN) α-2b to α-2a and ribavirin (RBV) in patients with recurrence of hepatitis C virus (HCV) infection after living donor liver transplantation. The patient was a 62-year-old man with liver cirrhosis due to HCV genotype 1b infection. The patient had 8 amino acid (aa) substitutions in the interferon sensitivity-determining region, and had substitutions for mutant and wild-type at aa70 and aa91, respectively, in the core region. The patient had minor genotype (GG) IL28B single nucleotide polymorphisms (rs8099917). He had initially received interferon α-2b and RBV for 2 years, and later developed hepatocellular carcinoma (HCC). After surgical resection of HCC, he subsequently received PEG-IFN α-2b and RBV for 1.5 years, without undetectable viremia during the treatment course. Due to recurrence of HCC, the patient received a living donor liver transplantation. Later on, hepatitis C relapsed. For the management of relapse, he received another course of PEG-IFN α-2b and RBV. However, breakthrough viremia occurred. PEG-IFN was thus switched from α-2b to α-2a and RBV for another 17 months. The patient eventually achieved a sustained viral response.

show abstract

Neutralizing antibodies in patients with chronic hepatitis C infection treated with (Peg)-interferon/ribavirin

Cited by 12 publications

References 24 publications

Measurements of HCV neutralizing antibodies and of HCV-specific CD4+ and CD8+ cells using hepatitis C virus pseudo-particles (HCVpp)

Measurements of HCV neutralizing antibodies and of HCV-specific CD4+ and CD8+ cells using hepatitis C virus pseudo-particles (HCVpp)

Neutralizing Antibodies in Patients with Chronic Hepatitis C, Genotype 1, against a Panel of Genotype 1 Culture Viruses: Lack of Correlation to Treatment Outcome

Achievement of Sustained Viral Response after Switching Treatment from Pegylated Interferon a-2b to a-2a and Ribavirin in Patients with Recurrence of Hepatitis C Virus Genotype 1 Infection after Liver Transplantation: A Case Report

Contact Info

Product

Resources

About